Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis.

Karani, Amanda; Felismino, Tiago Cordeiro; Diniz, Lara; Macedo, Mariana Petaccia; Silva, Virgilio Souza E; Mello, Celso Abdon

Karani, Amanda; Felismino, Tiago Cordeiro; Diniz, Lara; Macedo, Mariana Petaccia; Silva, Virgilio Souza E; Mello, Celso Abdon.

Afiliación

Karani A; Department of Medical Oncology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.
Felismino TC; Department of Medical Oncology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.
Diniz L; Department of Medical Oncology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.
Macedo MP; Department of Pathology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.
Silva VSE; Department of Medical Oncology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.
Mello CA; Department of Medical Oncology, AC Camargo Cancer Center, Sao Paulo 01509-000, Brazil.

Ecancermedicalscience ; 14: 1069, 2020.

Article en En | MEDLINE | ID: mdl-32728385

Palabras clave

anti-EGFR; colorectal carcinoma; prognosis; rechallenge; treatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Ecancermedicalscience Año: 2020 Tipo del documento: Article País de afiliación: Brasil

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google